4th Quarter - Report
NVG, LLC for PHRMA
Firm
Client
Income
$50,000
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
H.R. 2851 and S. 1327, Stop the Importation and Trafficking of Synthetic Analogues Act of 2017 Public Law No: 114-145, Ensuring Patient Access and Effective Drug Enforcement Act of 2016
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANDREA LARUE | — |
Copyright/Patent/Trademark CPT
Intellectual property and potential changes to the patent system, generally; S. 1390, Stronger Patents Act of 2017; S. 974, CREATES Act of 2017
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANDREA LARUE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.